AbSci Overview
- Founded
- 2011

- Status
- Private
- Employees
- 102

- Latest Deal Type
- Series E
- Latest Deal Amount
- $70M

- Investors
- 20
AbSci General Information
Description
Developer of biomanufacturing technologies intended to facilitate optimizable and scalable production of soluble recombinant monoclonal antibodies as well as other therapeutic proteins. The company engages in the development of novel production platforms for the large-scale production of recombinant proteins for therapeutic applications, enabling clients to reduce drug costs, accelerate development timelines and enable new biologic therapies to market.
Contact Information
- 101 East 6th Street
- Suite 350
- Vancouver, WA 98660
- United States
AbSci Timeline
AbSci Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Later Stage VC (Series E) | 22-Feb-2021 | $70M | 00000 | Completed | Generating Revenue | |
8. Debt - PPP | 28-Apr-2020 | 000.00 | Completed | Generating Revenue | ||
7. Later Stage VC (Series D) | 01-Feb-2020 | 0000 | 000.00 | Completed | Generating Revenue | |
6. Later Stage VC (Series C) | 30-May-2018 | 0000 | 000.00 | Completed | Generating Revenue | |
5. Later Stage VC (Series B) | 07-Aug-2017 | 00.00 | Completed | Generating Revenue | ||
4. Later Stage VC | 11-Apr-2016 | 00.00 | 00.00 | 0000 | Completed | Generating Revenue |
3. Accelerator/Incubator | 01-Jan-2013 | Completed | Generating Revenue | |||
2. Grant | Completed | Generating Revenue | ||||
1. Angel (individual) | Completed | Generating Revenue |
AbSci Comparisons
Industry
0000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAbSci Competitors (29)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Batavia Biosciences | Corporation | Leiden, Netherlands | 00 | 0000000000 | ||
0000000 | Formerly Accelerator/Incubator backed | San Francisco, CA | 0 | 000000&0 | ||
0000000 | Formerly VC-backed | Rockville, MD | 000 | 000.00 | 000000000 - | |
000000 00000000000 | Corporate Backed or Acquired | Richmond, CA | 000000000 - | |||
00000000 | Venture Capital-Backed | Düsseldorf, Germany | 00 | 0000000000 |
AbSci Executive Team (9)
AbSci Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Amrit Nagpal | Redmile Group | Board Member | 000 0000 |
Andreas Pihl | AbSci | Chief Operating Officer & Board Member | 000 0000 |
Daniel Gold Ph.D | AbSci | Board Member | 000 0000 |
Eli Casdin | Casdin Capital | Board Member | 000 0000 |
Gustavo Mahler Ph.D | Self | Board Member | 000 0000 |
AbSci Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAbSci Investors (20)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
ArrowMark Partners | Asset Manager | Minority | 000 0000 | 000000 0 | |
Casdin Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Merck Global Health Innovation Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Redmile Group | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Brian Vierra | Angel (individual) | Minority | 000 0000 | 000000 0 |
AbSci Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 | 12-Jan-2021 | 000000000000000000 | Decision/Risk Analysis | 0000 0000000 |
AbSci Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
00000000 | Decision/Risk Analysis | San Diego, CA | 0000 |